Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18319245 | MULTISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND CD38 AND 4-1BB, AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17904562 | ANTIBODY FRAGMENTS CONJUGATED TO PEG-PLGA NANOPARTICLES IMPROVE IMMUNOTHERAPY AGAINST CANCER CELLS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18034669 | DUAL TARGETING CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17444778 | USE OF BMMF1 REP PROTEIN AS A BIOMARKER FOR BREAST CANCER | Non-Final OA | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS |
| 18607961 | METHODS AND COMPOSITIONS RELATING TO HIGH-THROUGHPUT MODELS FOR ANTIBODY DISCOVERY AND/OR OPTIMIZATION | Non-Final OA | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 17255228 | COMPLEMENT INHIBITORS AND USES THEREOF | Non-Final OA | Universität Ulm |
| 18018471 | ANTI-PD-1 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18018687 | ARMED NK CELLS FOR UNIVERSAL CELL THERAPY | Non-Final OA | ICM (Institut De Cancerologie De Montpellier) |
| 17924161 | Anti-B7H3 Antibodies for the Treatment of Cancer | Non-Final OA | Y-mAbs Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy